01

Company

ferropharma group

Since 1989, at ferropharma we are changing the health care market by cutting value chains to decrease cost of drug development and drug availability.

One of our brand, EMELEMA® - Making Latest Medicine Available – is what we believe in and what drives the best talent from around the globe to join us.  

Our aim is to be known as the company that increases patient access to generic and innovative medicine. We focus on building bridges between markets, stakeholders and patients. Collectively, we believe in finding the most fair, straight and reliable provider for the distribution of Active Pharmaceutical Ingredients (API), Finished Dosage Forms (FDF) and services. Thanks to our dedicated teams in Brazil, China, Germany, India and Malta, we are using manufacturing plants for high quality products, in the most efficient way. We direct our attention on novel delivery systems and the provision of EU registered and manufactured drugs..

We made quality our priority. The EMA, FDA and ANVISA standards for APIs and FDFs are our benchmarks that we fulfill.

We operate worldwide but our core markets are China, Latin America and the European Union.

 

Carol

News

Lançamento da Dexmedetomidina - Launching Dexmedetomidine

Lançamento da Dexmedetomidina - Launching Dexmedetomidine

Graças a nossa equipe vibrante, enérgica e inovadora no Grupo Ferro Pharma, desde nossos escritórios na Ásia, passando pela Europa até a América Latina, conseguimos entrar no mercado com nossa primeira medicina intensiva.

Atualmente estamos lançando o medicamento ansiolítico Dexmedetomidina, uma versão genérica do Dexdor®, não apenas como um medicamento para reduzir a dor e relaxar usado em hospitais, mas também como um medicamento de apoio para médicos que ajudam a melhorar as vidas de pacientes infectados pela COVID-19.

Junto com nosso parceiro Sanval Comércio e Indústria, um dos principais fornecedores de medicina hospitalar no Brasil, que também é nosso parceiro de joint venture para a construção de nosso próprio selo BioBrasil®, estamos lançando o medicamento como um injetável de 100mcg/ml nos dias de hoje. Construímos a infra-estrutura para este evento há 5 anos e estamos felizes em ver nossos esforços terem sucesso desta forma. Com base em contratos já assinados, estamos lançando um pipeline de produtos para os próximos anos que fará crescer as vendas do Grupo Ferro Pharma em 7 vezes e mais.

---------------------------------

Thanks to our vibrant, energetic and innovative team in Ferro Pharma Group, from our offices in Asia, via Europe to Latin America we have been able to enter the market with our first intensive care medicine.

These days we are launching the anxiolytic drug Dexmedetomidine, a generic version of Dexdor®, not only as a pain reducing and relaxant drug used in hospitals, but also as a support medicine for doctors helping to improve the lives of COVID-19 infected patients.

Together with our partner Sanval Comércio e Indústria, one of the leading suppliers of hospital medicine in Brazil, who also is our joint venture partner for building up our own label BioBrasil®, we are launching the drug as a 100mcg/ml injectable these days. We have built the infrastructure for this event for 5 years now and are happy to see our efforts succeed this way. Based on already signed contracts we are launching a pipeline of products over the next years that will grow Ferro Pharma Group sales by 7 times and more.

New logo for ferropharma

New logo for ferropharma

With offices in Asia, Europe, South and North America, ferropharma has developed to become strong and globally active. Our global team is now also reflected in our logo.

And our new logo not only represents the unity of our entities, it also reflects on our core processes which we have been able to continuously streamline to become more efficient in our work in all locations.

Come join our group. It will be fun to have you on board. In case of interest please contact Verena via talent@ferropharma.group.

International success with Simvastatin

International success with Simvastatin

The collaboration of Ferro Pharma Group with Topfond SciTech has led to international success. The combination of in-depth focus on quality in combination with cost leadership has opened up the API business in an environment of fierce competition.

Within 9 months we have been able to acquire and contract long term supply partnerships with what we consider is the "who is who" in generic pharma, across three different continents. Thank you customers and Topfond SciTech for the trust you gave us as "newcomers" in the area of API business development and to give us the chance to prove we can do it.

More News

Ferro Pharma Europe Ltd. got an approval for a #COVID-19 antibody test

To all our friends who celebrate Chinese New Year

Happy Season’s Greetings Dear Peers!!!

Our Team

Andressa Cristina

Andreza Izidoro

Amanda Araújo

Amélie Bonnot

Bala Subramanyam Gurram

Bettina Böttcher

Carol von Gersdorff

Christian Schulenburg

Cypora F. Weisser

Iñaki Ilincheta

Marcelo Coelho

Maria Lucia Rodriguez

Massimo Briffa

Melanie Kuhagen

Orlando Marques da Silva

Paulo Lopes

Petra v.Z. Davenport

Rogerio Brown

Sandra Saliba

Sebastian Kähler

Dr. Verena Mack

Wayne Lin

Get in touch

ferropharma group

 

Phone: +49 40 306868 0
Fax: +49 40 306868 33

Email:


Please do not hesitate to use our
contact form or send us an email.
 

Thank you!

Contact form

Brasil

Alameda Madeira 328, Cj.1107
06454-010 - Alphaville
Barueri - SP

China

XIXI CENTURY CENTER, NO.136,
SHUANGLONG ROAD,
HANGZHOU, P. R. CHINA - 310030

Germany

Budapester Strasse 47
20359 Hamburg

India

Flat No. 501, Sai Balaji Hills-1,
Road No. 10, Madhavapuri Hills,
PJR Layout, Chandanagar,
Hyderabad – 500050

Malta

Ta’ Maggi Ind Park,
Admin Building - Level 2
Xghajra XJR 2306